Standard
Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC). / Morken, S.; Langer, S. W.; Sundlov, A.; Detlefsen, S.; Krogh, M.; Tabaksblat, E.; Hjortland, G. O.; Svensson, J. B.; Assmus, J.; Couvelard, A.; Perren, A.; Sorbye, H.
I:
Journal of Neuroendocrinology, Bind 34, Nr. S1, 2022, s. 181-181.
Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › fagfællebedømt
Harvard
Morken, S
, Langer, SW, Sundlov, A, Detlefsen, S, Krogh, M, Tabaksblat, E, Hjortland, GO, Svensson, JB, Assmus, J, Couvelard, A, Perren, A & Sorbye, H 2022, '
Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC)',
Journal of Neuroendocrinology, bind 34, nr. S1, s. 181-181.
https://doi.org/10.1111/jne.13108APA
Morken, S.
, Langer, S. W., Sundlov, A., Detlefsen, S., Krogh, M., Tabaksblat, E., Hjortland, G. O., Svensson, J. B., Assmus, J., Couvelard, A., Perren, A., & Sorbye, H. (2022).
Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC).
Journal of Neuroendocrinology,
34(S1), 181-181.
https://doi.org/10.1111/jne.13108Vancouver
Morken S
, Langer SW, Sundlov A, Detlefsen S, Krogh M, Tabaksblat E o.a.
Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC).
Journal of Neuroendocrinology. 2022;34(S1):181-181.
https://doi.org/10.1111/jne.13108Author
Morken, S. ; Langer, S. W. ; Sundlov, A. ; Detlefsen, S. ; Krogh, M. ; Tabaksblat, E. ; Hjortland, G. O. ; Svensson, J. B. ; Assmus, J. ; Couvelard, A. ; Perren, A. ; Sorbye, H. / Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC). I: Journal of Neuroendocrinology. 2022 ; Bind 34, Nr. S1. s. 181-181.
Bibtex
@article{8cd0f54a9d014b6c84f2ae70b81df492,
title = "Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC)",
keywords = "neuroendocrine neoplasm, neuroendocrine carcinoma, high-grade gastroenteropancreatic, everolimus, temozolomide",
author = "S. Morken and Langer, {S. W.} and A. Sundlov and S. Detlefsen and M. Krogh and E. Tabaksblat and Hjortland, {G. O.} and Svensson, {J. B.} and J. Assmus and A. Couvelard and A. Perren and H. Sorbye",
year = "2022",
doi = "10.1111/jne.13108",
language = "English",
volume = "34",
pages = "181--181",
journal = "Journal of Neuroendocrinology",
issn = "0953-8194",
publisher = "Wiley-Blackwell",
number = "S1",
note = "19th Annual ENETS Conference on the Diagnosis and Treatment of Neuroendocrine Tumor Disease ; Conference date: 10-03-2022 Through 11-03-2022",
}
RIS
TY - ABST
T1 - Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC)
AU - Morken, S.
AU - Langer, S. W.
AU - Sundlov, A.
AU - Detlefsen, S.
AU - Krogh, M.
AU - Tabaksblat, E.
AU - Hjortland, G. O.
AU - Svensson, J. B.
AU - Assmus, J.
AU - Couvelard, A.
AU - Perren, A.
AU - Sorbye, H.
PY - 2022
Y1 - 2022
KW - neuroendocrine neoplasm
KW - neuroendocrine carcinoma
KW - high-grade gastroenteropancreatic
KW - everolimus
KW - temozolomide
U2 - 10.1111/jne.13108
DO - 10.1111/jne.13108
M3 - Conference abstract in journal
C2 - 35253281
VL - 34
SP - 181
EP - 181
JO - Journal of Neuroendocrinology
JF - Journal of Neuroendocrinology
SN - 0953-8194
IS - S1
T2 - 19th Annual ENETS Conference on the Diagnosis and Treatment of Neuroendocrine Tumor Disease
Y2 - 10 March 2022 through 11 March 2022
ER -
